GCC Comprehensive Clinical Reference Guide — Evidence-Based Practice 2025
| Type | Colour | Characteristics |
|---|---|---|
| Necrotic | Black/Brown | Hard eschar or soft moist necrosis; devitalised; must assess stability |
| Slough | Yellow/Tan | Devitalised soft fibrinous tissue; stringy or mucinous; impedes healing |
| Granulation | Red/Pink | Healthy vascular tissue; granular, moist; bleeds easily; target tissue |
| Epithelialisation | Pink/White | New epithelium migrating from edges; fragile; do not disturb |
| Hypergranulation | Bright red raised | Overgranulation above wound margins; treat with foam pressure or silver |
White/grey soggy skin from excessive moisture; reduce exudate with absorbent dressing; apply barrier film/cream 3–5 cm from wound edge.
Superficial skin loss from enzymatic activity of exudate or friction; protect with zinc oxide paste or silicone barrier film; change dressing more frequently.
Redness: differentiate blanching (pressure/irritation) from non-blanching (deep tissue injury or infection spreading cellulitis requiring urgent review).
Firm, hardened tissue; sign of deep infection or oedema; measure extent (cm from wound edge) and monitor closely.
Hyperkeratotic skin common around diabetic foot wounds and venous ulcers; regular debridement required to allow accurate edge assessment.
Haemosiderin staining common in venous disease on darker skin tones (common in GCC population); differentiate from early cellulitis clinically.
Monitor healing over time. Decreasing score = healing progression. Score of 0 = healed wound.
| Parameter | 0 | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|---|
| Length × Width (cm²) | 0 | <0.3 | 0.3–0.6 | 0.7–1.0 | 1.1–2.0 | 2.1–3.0 |
| 6: 3.1–4.0 | 7: 4.1–8.0 | 8: 8.1–12.0 | 9: 12.1–24.0 | 10: >24.0 | ||
| Exudate Amount | None | Light | Moderate | Heavy | — | — |
| Tissue Type | Closed | Epithelial | Granulation | Slough | Necrotic | — |
| Dressing Type | Primary Indications | Exudate Level | Change Frequency | Key Precautions |
|---|---|---|---|---|
| Hydrocolloid DuoDERM, Comfeel |
Low–moderate exudate; autolytic debridement; partial thickness; protecting intact skin | Low–Moderate | 3–7 days (change when edge lifting >2 cm) | Avoid on infected wounds; yellow gel on removal is NORMAL (not pus) |
| Hydrogel Intrasite, NovaBay |
Dry/necrotic wounds rehydration; burns; painful wounds (cooling effect) | None–Low | Daily to every 3 days | Cover with secondary dressing; avoid on heavy exudate (maceration risk) |
| Alginate Kaltostat, Sorbsan |
High exudate; haemostasis; cavity packing; fungating wounds | Moderate–Heavy | Daily to every 3 days depending on exudate | Do NOT use on dry wounds (can desiccate); irrigate to remove; need secondary dressing |
| Foam Dressing Mepilex, Allevyn |
Moderate–heavy exudate; cavity wounds (cavity foam); post-op wounds; pressure injury prevention | Moderate–Heavy | 2–7 days (exudate dependent) | Silicone foam for fragile/periwound skin; ensure good adhesion to prevent shear |
| Silver Dressing Mepilex Ag, Aquacel Ag |
Critically colonised or infected wounds; biofilm management; 2-week treatment trial maximum | Low–Heavy | 2–7 days (product specific) | Limit to 2-week trial; reassess; avoid in patients with silver sensitivity; do not use indefinitely |
| Manuka Honey Medihoney, Activon |
Infected/malodorous wounds; debriding; biofilm; Manuka ≥18+ UMF required | Low–Moderate | Daily to every 3 days | Warn patient of initial stinging (osmotic effect); may increase exudate; check halal status per formulary |
| NPWT / VAC KCI VAC, Renasys |
Complex cavity wounds; dehisced surgical; grafts; high exudate; stimulate granulation | Heavy | Every 48–72 hours (continuous or intermittent mode) | Contraindicated: untreated osteomyelitis, malignancy in wound, unexplored fistula, exposed vessels/nerves |
| Hydrofibre Aquacel, Durafiber |
High exudate; fragile periwound skin; deep cavity; infected wounds (Ag version) | Moderate–Heavy | Daily to every 3 days | Gel-forming on contact; need secondary dressing; superior to alginate for fragile periwound |
| Iodine Iodosorb (cadexomer), Betadine |
Infected wounds; chronic infected sloughy wounds; cadexomer preferred for chronic wounds | Low–Moderate | Every 2–3 days (cadexomer); change when pale | Avoid in thyroid disorders, large wounds (systemic iodine absorption), pregnancy; limit use to short course |
| Biological MEBO, Collagen, Larval |
Non-healing chronic wounds; larval therapy for necrotic/sloughy wounds | Variable | Larval: every 48–72 hrs; collagen: per protocol | Larval therapy requires specialist prescribing; patient acceptance counselling; check GCC availability |
Silver dressings should be used as a 2-week treatment trial only, then reassessed:
Historically used; now discouraged — non-selective (damages granulation tissue), painful, promotes infection risk.
Pulsed lavage or syringe irrigation (19G needle/35 ml syringe) at 4–15 psi; removes loose debris and bacteria; use warmed normal saline.
High-pressure water beam simultaneously debrides and irrigates; precise; used in theatre or specialised wound clinic; reduces surgical theatre time.
| Clinical Scenario | Recommended Method | Rationale |
|---|---|---|
| Large necrotic burden, urgent | Sharp/surgical | Speed; improves NPWT uptake |
| Dry, non-infected necrosis | Autolytic (hydrogel) | Safe, rehydrates, selective |
| Sloughy, low infection risk | Autolytic or enzymatic | Selective removal |
| Infected, heavy biofilm | Sharp + antimicrobial dressing | Removes biofilm; addresses infection |
| MRSA-colonised diabetic foot | Larval therapy or UAWD + silver | Selective; anti-biofilm |
| Frail/palliative patient | Autolytic only | Comfort; minimise pain |
| Stage | Description | Clinical Features | Management |
|---|---|---|---|
| Stage 1 | Non-blanchable erythema | Intact skin; localised redness; may differ in darkly pigmented skin (darker/purple tone) | Offload immediately; barrier cream; reposition 2-hourly; SSKIN bundle |
| Stage 2 | Partial thickness | Open shallow wound or intact/ruptured blister; red-pink wound bed; no slough/eschar | Moist healing; foam or hydrocolloid; offloading; nutrition review |
| Stage 3 | Full thickness skin loss | Visible subcutaneous fat; slough may be present; undermining/tunnelling possible; no bone/muscle/tendon visible | Debridement; NPWT for cavities; nutrition; offloading; specialist review |
| Stage 4 | Full thickness tissue loss | Exposed bone/muscle/tendon/cartilage; slough/eschar; often undermining/tunnelling | Surgical referral; NPWT; osteomyelitis workup; nutritional support; MDT approach |
| Unstageable | Depth unknown | Full thickness but covered by slough/eschar; depth cannot be determined until debrided | Debride (except dry stable heel eschar); reassess stage post-debridement |
| Deep Tissue Injury | DTI — suspected | Intact/non-intact skin with deep purple/maroon localised area or blood-filled blister; rapid deterioration possible | Immediate full offloading; monitor closely; may evolve to Stage 3/4 within days |
≥3 NERDS criteria: treat with topical antimicrobial (silver/honey/iodine dressing). No systemic antibiotics required at this stage.
≥3 STONEES criteria: systemic antibiotics + urgent medical review. Wound swab + blood cultures if systemic signs.
Enter wound parameters below to receive evidence-based dressing recommendations, change frequency, and clinical alerts.